Related Experiment Videos
Adjuvant therapy for malignant melanoma
John P Stoutenburg1, Beth Schrope, Howard L Kaufman
1Division of Medical Oncology, Department of Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York 10032, USA.
Expert Review of Anticancer Therapy
|October 16, 2004
Summary
Malignant melanoma recurrence risk necessitates adjuvant therapy. This review covers interferon-alpha, immunotherapy, chemotherapy, and radiation, exploring new promising combinations for melanoma treatment.
Area of Science:
- Oncology
- Dermatology
Background:
- Malignant melanoma incidence is rising globally.
- Patients face significant recurrence risk post-surgery.
- Interferon-alpha has been the sole approved adjuvant therapy for 30 years.
Purpose of the Study:
- To review the rationale for adjuvant therapy in melanoma.
- To discuss current adjuvant treatment modalities.
- To outline novel and promising approaches for melanoma adjuvant therapy.
Main Methods:
- Literature review of adjuvant therapy for malignant melanoma.
- Discussion of interferon, immunotherapy, chemotherapy, and radiation therapy roles.
- Identification and summary of emerging treatment strategies.
Main Results:
- Interferon-alpha's long-standing role as an adjuvant therapy.
- Exploration of diverse therapeutic options beyond interferon.
- Identification of novel combinations with potential efficacy.
Conclusions:
- Adjuvant therapy is crucial for managing melanoma recurrence risk.
- Multiple treatment modalities exist, with ongoing research into novel combinations.
- Future melanoma management will likely involve personalized and combination therapies.